These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12872693)

  • 1. [Comparison of pharmacokinetics of saquinavir soft-gel capsule (SQV-SGC) combined with ritonavir (RTV), SQV hard-gel capsule with RTV, and SQV-SGC alone].
    Tsuchiya K; Hirabayashi Y; Imai K; Kikuchi Y; Tachikawa N; Genka I; Teruya K; Yasuoka A; Oka S; Kimura S
    Kansenshogaku Zasshi; 2003 Jun; 77(6):436-42. PubMed ID: 12872693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
    Veldkamp AI; van Heeswijk RP; Mulder JW; Meenhorst PL; Schreij G; van der Geest S; Lange JM; Beijnen JH; Hoetelmans RM
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):344-9. PubMed ID: 11468422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
    Cardiello PG; Monhaphol T; Mahanontharit A; van Heeswijk RP; Burger D; Hill A; Ruxrungtham K; Lange JM; Cooper DA; Phanuphak P
    J Acquir Immune Defic Syndr; 2003 Apr; 32(4):375-9. PubMed ID: 12640194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
    Cardiello PG; van Heeswijk RP; Hassink EA; Srasuebkul P; Mahanontharit A; Samor TM; Worarien W; Beijnen JH; Hoetelmans RM; Ruxrungtham K; Cooper DA; Lange JM; Phanuphak P
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):464-70. PubMed ID: 11981362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers.
    Kurowski M; Sternfeld T; Sawyer A; Hill A; Möcklinghoff C
    HIV Med; 2003 Apr; 4(2):94-100. PubMed ID: 12702129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
    Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
    Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.
    Buss N; Snell P; Bock J; Hsu A; Jorga K
    Br J Clin Pharmacol; 2001 Sep; 52(3):255-64. PubMed ID: 11560557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
    Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
    Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
    von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
    Jamois C; Smith P; Morrison R; Riek M; Patel A; Schmitt C; Morcos PN; Zhang X
    Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
    Bittner B; Riek M; Holmes B; Grange S
    Antivir Ther; 2005; 10(7):803-10. PubMed ID: 16312177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.
    Boffito M; Dickinson L; Hill A; Back D; Moyle G; Nelson M; Higgs C; Fletcher C; Mandalia S; Gazzard B; Pozniak A
    Antivir Ther; 2004 Jun; 9(3):423-9. PubMed ID: 15259905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women.
    Acosta EP; Bardeguez A; Zorrilla CD; Van Dyke R; Hughes MD; Huang S; Pompeo L; Stek AM; Pitt J; Watts DH; Smith E; Jiménez E; Mofenson L;
    Antimicrob Agents Chemother; 2004 Feb; 48(2):430-6. PubMed ID: 14742191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group.
    Gisolf EH; Jurriaans S; Pelgrom J; van Wanzeele F; van der Ende ME; Brinkman K; Borst MJ; de Wolf F; Japour AJ; Danner SA
    AIDS; 2000 Mar; 14(4):405-13. PubMed ID: 10770543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.
    King JR; Kakuda TN; Paul S; Tse MM; Acosta EP; Becker SL
    J Clin Pharmacol; 2007 Feb; 47(2):201-8. PubMed ID: 17244771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
    Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
    Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection.
    Perry CM; Noble S
    Drugs; 1998 Mar; 55(3):461-86. PubMed ID: 9530549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.
    Kilby JM; Sfakianos G; Gizzi N; Siemon-Hryczyk P; Ehrensing E; Oo C; Buss N; Saag MS
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2672-8. PubMed ID: 10991842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients.
    Merry C; Barry MG; Mulcahy F; Ryan M; Heavey J; Tjia JF; Gibbons SE; Breckenridge AM; Back DJ
    AIDS; 1997 Mar; 11(4):F29-33. PubMed ID: 9084785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.